These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31770786)

  • 1. [Clinical Decision Making for Treatment of Diabetic Macular Oedema with DEX Implant: a Consensus Paper].
    Augustin AJ; Feltgen N; Haritoglou C; Hoerauf H; Maier MM; Mardin CY; Schargus M
    Klin Monbl Augenheilkd; 2021 Jan; 238(1):73-84. PubMed ID: 31770786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expert recommendations for the management of diabetic macular edema with intravitreal dexamethasone implant: A Turkish Delphi study.
    Batıoğlu F; Yanık Ö; Saatçi AO; Eldem B; Akkın C; Afrashi F; Özdemir H; Menteş J; Güngör K; Karabaş L; Karaçorlu M; Demircan N; Koçak N; Kır N; Ünlü N; Avcı R; Arvas S; Dündar SO; Kadayıfçılar S; Kaynak S; Özdek Ş; Ovalı T
    Eur J Ophthalmol; 2023 Jan; 33(1):398-407. PubMed ID: 35924358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations for the management of diabetic macular oedema with intravitreal dexamethasone implant: A national Delphi consensus study.
    Kodjikian L; Baillif S; Couturier A; Creuzot-Garcher C; Delyfer MN; Matonti F; Weber M
    Eur J Ophthalmol; 2022 Sep; 32(5):2845-2856. PubMed ID: 34779302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema.
    Busch C; Zur D; Fraser-Bell S; Laíns I; Santos AR; Lupidi M; Cagini C; Gabrielle PH; Couturier A; Mané-Tauty V; Giancipoli E; Ricci GD; Cebeci Z; Rodríguez-Valdés PJ; Chaikitmongkol V; Amphornphruet A; Hindi I; Agrawal K; Chhablani J; Loewenstein A; Iglicki M; Rehak M;
    Acta Diabetol; 2018 Aug; 55(8):789-796. PubMed ID: 29730822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dexamethasone implants in patients with diabetic macular edema undergoing cataract surgery: Italian expert panel consensus statements.
    Alessio G; Boscia F; Caporossi A; Panozzo G; Reibaldi M; Staurenghi G; Varano M; Bandello F
    Eur J Ophthalmol; 2021 May; 31(3):1122-1127. PubMed ID: 32635762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COMPARISON OF INTRAVITREAL DEXAMETHASONE IMPLANT AND AFLIBERCEPT IN PATIENTS WITH TREATMENT-NAIVE DIABETIC MACULAR EDEMA WITH SEROUS RETINAL DETACHMENT.
    Ozsaygili C; Duru N
    Retina; 2020 Jun; 40(6):1044-1052. PubMed ID: 30950970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features.
    Hatz K; Ebneter A; Tuerksever C; Pruente C; Zinkernagel M
    Ophthalmologica; 2018; 239(4):205-214. PubMed ID: 29402873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 0.19-mg Fluocinolone Acetonide Implant for the Treatment of Diabetic Macular Edema: An Expert Consensus.
    Kolomeyer AM; Eichenbaum DA; Kiernan DF; Suñer IJ; Hariprasad SM
    Ophthalmic Surg Lasers Imaging Retina; 2023 Mar; 54(3):166-173. PubMed ID: 36944067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
    Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VISUAL OUTCOMES IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE IMPLANT IN ROUTINE CLINICAL PRACTICE.
    Urbančič M; Gardašević Topčić I; Matović K
    Acta Clin Croat; 2021 Dec; 60(4):602-608. PubMed ID: 35734494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of diabetic macular edema with intravitreal dexamethasone implants: Expert recommendations using a Delphi-based approach.
    Giovannini A; Parravano M; Ricci F; Bandello F
    Eur J Ophthalmol; 2019 Jan; 29(1):82-91. PubMed ID: 29882421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study.
    Augustin AJ; Kuppermann BD; Lanzetta P; Loewenstein A; Li XY; Cui H; Hashad Y; Whitcup SM;
    BMC Ophthalmol; 2015 Oct; 15():150. PubMed ID: 26519345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dexamethasone intravitreal implant in diabetic macular oedema refractory to anti-vascular endothelial growth factors: the AUSSIEDEX study.
    Mitchell P; Arnold J; Fraser-Bell S; Kang HK; Chang AA; Tainton J; Simonyi S
    BMJ Open Ophthalmol; 2023 Aug; 8(1):. PubMed ID: 37541745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.
    Maturi RK; Glassman AR; Liu D; Beck RW; Bhavsar AR; Bressler NM; Jampol LM; Melia M; Punjabi OS; Salehi-Had H; Sun JK;
    JAMA Ophthalmol; 2018 Jan; 136(1):29-38. PubMed ID: 29127949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healthcare resource use and costs of diabetic macular oedema for patients with antivascular endothelial growth factor versus a dexamethasone intravitreal implant in Korea: a population-based study.
    Cho H; Choi KS; Lee JY; Lee D; Choi NK; Lee Y; Bae S
    BMJ Open; 2019 Sep; 9(9):e030930. PubMed ID: 31542758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anatomical effects of dexamethasone intravitreal implant in diabetic macular oedema: a pooled analysis of 3-year phase III trials.
    Danis RP; Sadda S; Li XY; Cui H; Hashad Y; Whitcup SM
    Br J Ophthalmol; 2016 Jun; 100(6):796-801. PubMed ID: 26581718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results.
    Busch C; Fraser-Bell S; Iglicki M; Lupidi M; Couturier A; Chaikitmongkol V; Giancipoli E; Rodríguez-Valdés PJ; Gabrielle PH; Laíns I; Santos AR; Cebeci Z; Amphornphruet A; Degenhardt V; Unterlauft JD; Cagini C; Mané-Tauty V; D'Amico Ricci G; Hindi I; Agrawal K; Chhablani J; Loewenstein A; Zur D; Rehak M;
    Acta Diabetol; 2019 Dec; 56(12):1341-1350. PubMed ID: 31541334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Foveal eversion patterns in diabetic macular edema.
    Arrigo A; Saladino A; Aragona E; Amato A; Capone L; Bianco L; Lattanzio R; Bandello F; Battaglia Parodi M
    Sci Rep; 2022 Jul; 12(1):13097. PubMed ID: 35907954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of dexamethasone versus bevacizumab on regression of hard exudates in diabetic maculopathy: data from the BEVORDEX randomised clinical trial.
    Mehta H; Fraser-Bell S; Yeung A; Campain A; Lim LL; Quin GJ; McAllister IL; Keane PA; Gillies MC
    Br J Ophthalmol; 2016 Jul; 100(7):1000-1004. PubMed ID: 26537156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early-switch versus late-switch in patients with diabetic macular edema: a cost-effectiveness study.
    Ruiz-Moreno JM; Ruiz-Medrano J
    Graefes Arch Clin Exp Ophthalmol; 2023 Apr; 261(4):941-949. PubMed ID: 36370170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.